SCHEMBL1733584

SCHEMBL1733584

CC1=CN(CO)CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9687359 0.77
SCHEMBL16592678 0.61
SCHEMBL5077215 0.60
SCHEMBL15836129 0.52
SCHEMBL3117258 0.50
SCHEMBL5899081 0.49
SCHEMBL4645948 0.47
SCHEMBL1936976 0.46
SCHEMBL1351735 0.43
Ethylene Glycol SCHEMBL3080883 0.41 ALDH1A1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1467976-B1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2011-11-23 EP disclosed
WO-2011081310-A3 PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME 한국기초과학지원연구원 (KR) 2011-10-27 WO disclosed
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES BAXTER ANDREW 2010-04-01 US disclosed
US-7662825-B2 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma ASTRAZENECA AB (SE) 2010-02-16 US disclosed
US-20060025423-A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases ASTRAZENECA AB (SE) 2006-02-02 US disclosed
CN-1639132-A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases ASTRAZENECA AB (SE) 2005-07-13 CN disclosed
EP-1467976-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES AstraZeneca AB (SE) 2004-10-20 EP disclosed
WO-2003059893-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-07-24 WO disclosed